Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic

Drug Delivery

Volumn 23, Issue 4, 2016, Pages 1335-1343

  Tran, Tuan Hiep ^a   Chu, Duc Thanh ^b   Truong, Duy Hieu ^a   Tak, Jin Wook ^a   Jeong, Jee Heon ^a   Hoang, Van Luong ^b   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b VIETNAM MILITARY MEDICAL UNIVERSITY   (Viet Nam)

Author keywords

Histone deacetylases inhibitor; nanostructured lipid carriers; oral bioavailability; vorinostat

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID; NANOCARRIER; VORINOSTAT; DELAYED RELEASE FORMULATION; DRUG CARRIER; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; NANOMATERIAL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; ELECTROPHORETIC MOBILITY; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; MEAN RESIDENCE TIME; MICROEMULSION; MOLECULAR WEIGHT; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; HUMAN; METABOLISM;

CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LIPIDS; NANOPARTICLES; NANOSTRUCTURES;

EID: 84975303450     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.991432     Document Type: Article

References (37)

1. M.Á.Aznar, B.Lasa-Saracíbar, A.Estella-Hermoso De Mendoza,. (2013). Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 454:720–6
2. A.Beloqui, M.Á.Solinís, A.R.Gascón,. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Controll Release 166:115–23
3. R.Bhandari, I.P.Kaur. (2013). Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 441:202–12
4. J.E.Bolden, M.J.Peart, R.W.Johnstone. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–84
5. M.L.Bondì, E.F.Craparo, G.Giammona,. (2007). Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv 14:61–7
6. F.Brugè, E.Damiani, C.Puglia,. (2013). Nanostructured lipid carriers loaded with CoQ10: effect on human dermal fibroblasts under normal and UVA-mediated oxidative conditions. Int J Pharm 455:348–56
7. H.Bunjes, K.Westesen, M.H.Koch. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129:159–73
8. Y.Cai, C.Yap, Z.Wang,. (2010). Solubilization of vorinostat by cyclodextrins. J Clin Pharm Ther 35:521–6
9. P.Chandran, A.Kavalakatt, G.L.Malarvizhi,. (2014). Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomed-Nanotechnol 10:721–32
10. C.-C.Chen, T.-H.Tsai, Z.-R.Huang,. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–82
11. M.Cirri, M.Bragagni, N.Mennini,. (2012). Development of a new delivery system consisting in “drug – in cyclodextrin – in nanostructured lipid carriers” for ketoprofen topical delivery. Eur J Pharm Biopharm 80:46–53
12. D.Delgado, A.Del Pozo-Rodríguez, M.Á.Solinís,. (2011). Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur J Pharm Biopharm 79:495–502
13. N.Dudhipala, K.Veerabrahma. (2014). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery Early online:1–10. doi:10.3109/10717544.2014.914986
14. P.Dwivedi, R.Khatik, K.Khandelwal,. (2014). Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 466:321–7
15. W.Hong, D.Chen, L.Jia,. (2014). Thermo- and pH-responsive copolymers based on PLGA-PEG-PLGA and poly(l-histidine): synthesis and in vitro characterization of copolymer micelles. Acta Biomater 10:1259–71
16. L.Jia, J.Shen, D.Zhang,. (2012). In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol 50:523–9
17. L.-J.Jia, D.-R.Zhang, Z.-Y.Li,. (2010). Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 17:11–18
18. W.K.Kelly, O.A.O’connor, L.M.Krug,. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–31
19. R.Konsoula & M.Jung. (2008). In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm 361:19–25
20. A.Kumar, A.Ahuja, J.Ali,. (2014). Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells. Drug Delivery Early online:1–16. doi:10.3109/10717544.2014.909906
21. X.Lin, X.Li, L.Zheng,. (2007). Preparation and characterization of monocaprate nanostructured lipid carriers. Colloid Surface A 311: 106–11
22. P.Marks. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351–6
23. P.A.Marks, V.M.Richon, T.Miller,. (2004). Histone deacetylase inhibitors. Adv Cancer Res 91:137–68
24. R.Minelli, S.Occhipinti, C.Gigliotti,. (2013). Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. Brit J Pharm 170:233–44
25. E.A.Mohamed, Y.Zhao, M.M.Meshali,. (2012). Vorinostat with sustained exposure and high solubility in poly (ethylene glycol)-b-poly (dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci 101:3787–98
26. S.V.Mussi, R.C.Silva, M.C.D.Oliveira,. (2013). New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 48:282–90
27. B.K.Poudel, N.Marasini, T.H.Tran,. (2012). Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment. Chem Pharm Bull 60:1409–18
28. T.Ramasamy, T.H.Tran, H.J.Cho,. (2013). Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm Res 31:1302–14
29. V.Richon. (2006). Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Brit J Cancer 95:S2–6
30. R.Tiwari, K.Pathak. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43
31. T.H.Tran, B.K.Poudel, N.Marasini,. (2013). Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Inter J Pharma 443:50–7
32. T.H.Tran, T.Ramasamy, D.H.Truong,. (2014). Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res 31:1978–88
33. M.-J.Tsai, Y.-B.Huang, P.-C.Wu,. (2011). Oral apomorphine delivery from solid lipid nanoparticleswith different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100:547–57
34. M.-J.Tsai, P.-C.Wu, Y.-B.Huang,. (2012). Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 423:461–70
35. P.Xu, Q.Yin, J.Shen,. (2013). Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int J Pharm 454:21–30
36. H.Yuan, C.-Y.Chen, G.-H.Chai,. (2013). Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm 10:1865–73
37. C.-Y.Zhuang, N.Li, M.Wang,. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85